Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 5/20 | 0.79 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.73 |
| ▸ | ABL1 | P00519 | 3/20 | 0.67 |
| ▸ | BCR | P11274 | 3/20 | 0.67 |
| ▸ | SRC | P12931 | 2/20 | 0.67 |
| ▸ | EGFR | P00533 | 1/20 | 0.67 |
| ▸ | PRKACA | P17612 | 1/20 | 0.67 |
| ▸ | PRKACG | P22612 | 1/20 | 0.67 |
| ▸ | PRKACB | P22694 | 1/20 | 0.67 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.63 |
| ▸ | SYK | P43405 | 4/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | CDK4 | P11802 | 3/20 | 0.56 |
| ▸ | CDK2 | P24941 | 3/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14530851 | 0.95 | PLK1 (0.75) | PLK1CAMK2DABL1BCRSRC | |
| SCHEMBL4737537 | 0.91 | SYK (0.67) | PLK1CAMK2DABL1BCRSRC | |
| SCHEMBL823915 | 0.91 | CAMK2D (0.82) | PLK1CAMK2DABL1BCRSRC | |
| SCHEMBL4907230 | 0.88 | PLK1 (1.00) | PLK1CAMK2DABL1BCRSRC | |
| SCHEMBL2944088 | 0.88 | ABL1 (0.64) | PLK1CAMK2DABL1BCRSRC | |
| SCHEMBL27444270 | 0.87 | PLK1 (0.78) | PLK1CAMK2DABL1BCRSRC | |
| SCHEMBL12801709 | 0.85 | CAMK2D (1.00) | PLK1CAMK2DABL1BCRSRC | |
| SCHEMBL4905928 | 0.85 | PLK1 (0.72) | PLK1CAMK2DABL1BCRCDK5 | |
| SCHEMBL2945641 | 0.84 | MAPK8 (0.67) | PLK1ABL1BCRSRCSYK | |
| SCHEMBL12801287 | 0.84 | PLK1 (0.82) | PLK1CAMK2DABL1BCRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2172460-A1 | Compositions useful as inhibitors of JAK and other protein kinases | Vertex Pharmaceuticals Incorporated (US) | 2010-04-07 | — | — | EP | disclosed |
| EP-1562911-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2010-01-06 | — | — | EP | disclosed |
| US-7312227-B2 | Compositions useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1562911-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040147507-A1 | Compositions useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-07-29 | — | — | US | disclosed |
| WO-2004041789-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147507-A1 | Compositions useful as inhibitors of JAK and other protein kinases | JAK1, JAK2, JAK3 | PLK1 150/4885CAMK2D 442/4885ABL1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.